LON:OPTI OptiBiotix Health Interim Earnings Report GBX 6.11 -0.14 (-2.24%) As of 10:56 AM Eastern ProfileEarnings History OptiBiotix Health EPS ResultsActual EPS-GBX 1.15Consensus EPS N/ABeat/MissN/AOne Year Ago EPSN/AOptiBiotix Health Revenue ResultsActual RevenueN/AExpected RevenueN/ABeat/MissN/AYoY Revenue GrowthN/AOptiBiotix Health Announcement DetailsQuarterInterimDate9/16/2025TimeBefore Market OpensConference Call DateN/AConference Call TimeN/AConference Call ResourcesEarnings HistoryCompany Profile OptiBiotix Health Earnings HeadlinesOptiBiotix Improves Revenue and Margins as Focus Shifts Toward Sustainable Profitability (OPTI)May 28, 2026 | uk.finance.yahoo.comOptiBiotix to Present Upgraded SweetBiotix Sugar Alternative at London Shareholder Event (OPTI)May 14, 2026 | uk.finance.yahoo.comYour book is insideThe "Sucker's Bet" Most New Options Traders Fall For Most people who try options lose money the same way. They don't know the rules. They don't know what to avoid. And they hand their account to Wall Street on a silver platter. Normally $29.97. Free today.June 3 at 1:00 AM | Profits Run (Ad)OptiBiotix shares rise after company says it will not sell SkinBioTherapeutics stakeFebruary 17, 2026 | finance.yahoo.comOptiBiotix Health hails record start to 2026 after securing new ordersJanuary 21, 2026 | lse.co.ukAIM WINNERS & LOSERS: OptiBiotix and Ixico rise on deal winsNovember 17, 2025 | lse.co.ukSee More OptiBiotix Health Headlines Get Earnings Announcements in your inboxWant to stay updated on the latest earnings announcements and upcoming reports for companies like OptiBiotix Health? Sign up for Earnings360's daily newsletter to receive timely earnings updates on OptiBiotix Health and other key companies, straight to your email. Email Address About OptiBiotix HealthOptiBiotix Health (LON:OPTI) (AIM: OPTI), which was formed in March 2012, brings science to the development of compounds which modify the human microbiome - the collective genome of the microbes in the body - in order to prevent and manage human disease and promote wellness. OptiBiotix has an extensive R&D programme working with leading academics in the development of microbial strains, compounds, and formulations which are used as active ingredients and supplements. More than twenty international food and healthcare supplement companies have signed agreements with OptiBiotix to incorporate their human microbiome modulators into a wide range of food products and drinks. OptiBiotix is also developing its own range of consumer supplements and health products. The Company's current areas of focus include obesity, cardiovascular health, and diabetes. This communication is a "Reach" announcement. Reach is a non-regulatory news service. By using this service an issuer is confirming that the information contained in this announcement is of a non-regulatory nature. Information required to be notified under the AIM Rules for Companies, Market Abuse Regulation or other regulation would be disseminated as an RNS regulatory announcement and not on RNS Reach.View OptiBiotix Health ProfileRead more More Earnings Resources from MarketBeat Earnings Tools Today's Earnings Tomorrow's Earnings Next Week's Earnings Upcoming Earnings Calls Earnings Newsletter Earnings Call Transcripts Earnings Beats & Misses Corporate Guidance Earnings Screener Latest Articles Palo Alto Networks Accelerates Growth 31% on AI DemandUrban Outfitters Stock Stalls Despite Another Strong QuarterMarvell’s AI Moment Raises a Bigger Question for Amazon and ServiceNowHIVE Earnings Highlight AI Ambitions Beyond Bitcoin MiningMongoDB Is the Latest SaaS Apocalypse Victim to Say "Not Today"Dollar General Signals Reversal With 60% Rebound PotentialKohl's Stock Soars After Better-Than-Feared Quarter Upcoming Earnings Ciena (6/4/2026)Oracle (6/10/2026)Adobe (6/11/2026)Accenture (6/18/2026)FedEx (6/23/2026)Micron Technology (6/24/2026)NIKE (6/30/2026)Delta Air Lines (7/9/2026)Fastenal (7/13/2026)Bank of America (7/14/2026) Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.